InMed Pharmaceuticals (STU:MWG) FFO


STU:MWG InMed Pharmaceuticals Inc STU:MWG
28 GF Score
Price €1.43
GF Value €0.81
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is InMed Pharmaceuticals FFO?

FFO (Funds from operations) only applies to REITs.

STU:MWG
28GF Score
InMed Pharmaceuticals Inc STU:MWG
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is InMed Pharmaceuticals (STU:MWG) Overvalued in 2026?

Based on GuruFocus' analysis, InMed Pharmaceuticals stock appears to be overvalued. The current stock price of €1.43 is trading 76.5% above its estimated GF Value™ of €0.81. GuruFocus considers InMed Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for STU:MWG:

  • FFO:
  • GF Value™: €0.81 vs. price of €1.43 (76.5% above fair value)
  • GF Score™: 28/100 with 4 warning signs

No single metric tells the full story. See the STU:MWG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


InMed Pharmaceuticals Business Description

Other Exchanges INM:USA
Address 885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8
InMed Pharmaceuticals Inc is a pharmaceutical company developing a pipeline of disease-modifying small molecule drug candidates targeting CB1 and CB2 receptors. The company's pipeline consists of three separate programs in the treatment of Alzheimer's, ocular and dermatological indications.
28GF Score

Get the complete analysis for STU:MWG

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.43
Price
€0.81
GF Value